PORTON DOWN, England and SAN FRANCISCO, Dec. 16 /PRNewswire/ -- Enigma Diagnostics Limited, the decentralized and point-of-care molecular diagnostics company, announced today that it has signed a term sheet for two patent license agreements with Roche Molecular Systems, Inc. (RMS).
The licenses will provide Enigma full access under patents owned or licensed by RMS and its affiliates to practice HybProbe real-time PCR chemistry and will allow Enigma to commercialize HybProbe diagnostic PCR tests for human and veterinary in vitro diagnostics on a worldwide basis, complementing Enigma's existing license under patents owned by Celera Diagnostics for real-time PCR thermal cyclers.
Enigma is currently developing a series of multiplexed, HybProbe assays for infectious diseases including chlamydia, influenza and MRSA. These tests will be combined with Enigma's revolutionary and fully automated real-time PCR system, the Enigma ML, to enable one-step molecular testing at point of care.
Financial terms were not disclosed.
UK Contact:
Enigma Diagnostics
Deborah Cordingley
deborah.cordingley@enigmadiagnostics.com
+44 1980 590131
US Contact:
Richard Lewis Communications, Inc.
212-827-0020
Megan Dubrowski - Media
mdubrowski@rlcinc.com
Cecelia Heer - Investors
cheer@rlcinc.com
About Enigma Diagnostics Limited
Enigma Diagnostics Limited is a private UK-based company specializing in developing the next generation of rapid molecular diagnostic instrument platforms for decentralized and point-of-care settings.
Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (po
'/>"/>
| SOURCE Enigma Diagnostics Limited Copyright©2008 PR Newswire. All rights reserved |